Promising Outcomes of Transcatheter Mitral Valve Replacement in Complex Patients

Courtesy of Dr. Carlos Fava.

The risk of repeat surgical mitral valve repair involves 6% to15% mortality at 30 days, even close to 20% in acute cases. However, mortality can rise to over 40% when it comes to a third or fourth surgical intervention. 

Resultados alentadores en la válvula mitral percutánea en los pacientes complejos

One of the solutions to this serious problem is transcatheter mitral valve replacement (TMVR) with balloon expandable valves in the mitral valve, being it MVinV, MVinRing or in patients with severe annular calcification (VIMAC), which also involves significantly higher complications.

The study included 903 patients. 680 received MVinV, 123 MVinRing, and 10 VIMAC.

Mean age was 75, 60% were women, 65% had atrial fibrillation, 90% were functional class III-IV and had 10% STS. 

Those presenting VIMAC had more prior TMVR and FFR was lower in MVinRing patients.


Read also: Virtual ACC 2020 | Unlike in TAVR, the Number of Mitral Valve Surgeries Does Not Improve the Outcomes of Transcatheter Mitral Valve Repairs.


The valve most used was SAPIENS 3, most used diameter was 29 in MVinV and VIMAC, and 26 in MVinRing.

The highest success rate was in MVinV and MVinRing vs. VIMAC (87.9%, 90.9% and 82.9% p<0.001), left ventricular outflow tract obstruction was more frequent in VIMAC.

In-hospital mortality was higher in VIMAC (MVinV 6.3%, MVinRing 4.9% and VIMAC 10% p=0.004).


Read also: Percutaneous Annuloplasty in Functional Mitral Regurgitation vs. Sham Procedure.


At 30 days, mortality was higher in VIMAC (MVinV=8.1%, MVinRing=11.5%, ViMAC=21.8%; P=0.003), there were no differences in mitral gradient and the presence of mitral regurgitation <1+. Even though most patients improved to functional class I-II, though not as much among VIMAC patients (MVinV=84.2%, MVinRing=81.8%, and ViMAC=62.9%; P=0.007).

Conclusion

The use of a transcatheter balloon expandable valve in MVinV was associated to lower mortality at 30 days (lower than the preceding STS score) and better short-term evolution vs MVinRing or VIMAC. At 30 days, all patients improved their functional class and transcatheter valve performance remained stable. 

Courtesy of Dr. Carlos Fava.

Original Title: Thirty-Day Outcomes of Transcatheter Mitral Valve Replacement for Degenerated Mitral Bioprostheses (Valve-in-Valve), Failed Surgical Rings (Valve-in-Ring), and Native Valve With Severe Mitral Annular Calcification (Valve-in- Mitral Annular Calcification) in the United States. Data From the Society of Thoracic Surgeons/American College of Cardiology / Transcatheter Valve Therapy Registry.

Reference: Mayra Guerrero, et al. Circ Cardiovasc Interv. 2020;13:e008425. DOI:10.1161/CIRCINTERVENTIONS.119.008425.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...